Фурамаг

General characteristics. Structure:

Active agent: фуразидин potassium of 25 mg that corresponds to the maintenance of a furazidin of 21.85 mg

Excipients: potassium a carbonate - 6.3 mg, magnesium a hydroxycarbonate - 25 mg, talc of 1.5 mg.

Active agent: фуразидин potassium of 50 mg that corresponds to the maintenance of a furazidin of 43.7 mg

Excipients: potassium a carbonate - 12.6 mg, magnesium a hydroxycarbonate - 50 mg, talc - 3 mg.

Pharmacological properties:

The antimicrobic broad-spectrum agent relating to group of nitrofurans.
Resistance to Furamagu develops slowly and does not reach high degree.
It is active concerning gram-positive cocci: Streptococcus spp., Staphylococcus spp.; gram-negative sticks: Escherichia coli, Salmonella spp., Shigella spp., Proteus mirabilis, Klebsiella spp., Enterobacter spp.; protozoa: Lamblia intestinalis and other microorganisms, resistant to antibiotics.
Concerning Staphylococcus spp., Escherichia coli, Aerobacter aerogenes, Bacterium citrovorum, Proteus mirabilis, Proteus morganii Furamag®, in comparison with other nitrofurans, is more active.
Фурамаг® shows higher activity to Enterococcus faecalis, Staphylococcus spp. in comparison with other groups of antibacterial drugs.
Against the most part of bacteria bacteriostatic concentration makes from 1:100 000 to 1:200 000. Bactericidal concentration is approximately twice more.
Under the influence of nitrofurans in microorganisms there is a suppression of a respiratory chain and cycle of tricarboxylic acids (tricarbonic acid cycle), and also oppression of other biochemical processes of microorganisms therefore there is a destruction of their cover or cytoplasmic membrane.
As a result of effect of nitrofurans microorganisms emit less toxins in this connection improvement of the general condition of the patient is possible even before the expressed suppression of growth of microflora. Nitrofurans, unlike many other antimicrobic means, not only do not oppress immune system of an organism, and on the contrary activate it: raise a caption of a complement and ability of leukocytes to englobe microorganisms. Nitrofurans stimulate a leukopoiesis in therapeutic doses.

Pharmacokinetics. Absorption
After administration of drug inside фуразидин it is absorbed in thin department of intestines by passive diffusion. Absorption of nitrofurans from a distal segment of a small intestine exceeds absorption from proximal and medial segments respectively in 2 and 4 times (it is necessary to consider at simultaneous treatment of urogenital infections and gastrointestinal diseases, in particular chronic enterit). Nitrofurans are badly soaked up from a large intestine.
Cmax in a blood plasma remains from 3 to 7 or 8 h, in urine фуразидин it is found in 3-4 h.
Being mix of potassium salt of a furazidin and magnesium of a carbonate of the basic in the ratio 1:1, Furamag® at peroral introduction has higher bioavailability, than idle time фуразидин (after reception of the capsule of Furamaga in acid medium of a stomach there is no transformation of a furazidin of potassium in badly soluble фуразидин).

Distribution.
In an organism фуразидин it is distributed evenly. High content of active ingredient in a lymph is clinically important (spread of an infection on lymphatic ways detains). In bile concentration is several times higher than it, than in serum, and in liquor - several times below, than in serum. In saliva the maintenance of a furazidin makes 30% of its concentration in serum. Concentration of a furazidin in blood and fabrics rather small that is connected with its bystry allocation, at the same time concentration in urine is much higher, than in blood.

Metabolism.
It biotransformirutsya slightly (<10%).

Removal.
Unlike nitrofurantoin (furadonin), after reception of Furamaga рН urine does not change. In 4 h after administration of drug concentration of a furazidin in urine considerably exceeds that concentration which is formed after reception of the same dose of a furagin.
It is removed by kidneys by glomerular filtering and canalicular secretion (85%), partially is exposed to the return reabsorption in tubules. At low concentration of a furazidin in urine process of filtering and secretion prevails, at high concentration secretion decreases and the reabsorption increases. Furazidin, being weak acid in an aciduria does not dissociate, is exposed to an intensive reabsorption that can strengthen development of system side effects. At alkali reaction of urine removal of a furazidin amplifies.

Pharmacokinetics in special clinical cases.
At decrease in secretory function of kidneys intensity of metabolism increases.

Indications to use:

The infections caused by sensitive microorganisms:

— urogenital infections (acute cystitis, uretrita, pyelonephritises);
— gynecologic infections;
— infections of skin and soft tissues;
— the heavy infected burns;
— with the preventive purpose at urological operations (including tsistoskopiya, catheterizations).

Route of administration and doses:

Drug should be accepted inside after food, washing down with a large amount of liquid.
The adult appoint 3 on 50-100 mg
To children appoint on 25-50 mg 3 (but no more than 5 mg/kg of body weight in days).
Course of treatment of 7-10 days. In need of repetition of a course of treatment it is necessary to take a break within 10-15 days.
For prevention of an infection (including at urological operations, a tsistoskopiya, catheterization) drug is appointed the adult on 50 mg, children - on 25 mg once in 30 min. prior to the procedure.
In case of the admission of administration of drug, the next dose should be accepted in usual time. Not to accept the doubled dose for compensation of the passed dose.

Features of use:

For reduction of probability of development of side effects of Furamag® wash down with a large amount of liquid.
At emergence of side effects use of drug should be stopped (the toxic phenomena are more often shown at patients with reduced secretory function of kidneys).
The patient has to inform the doctor on any side effects arising during treatment by drug.
During treatment the patient is recommended to refrain from the use of alcoholic beverages as strengthening of side effects is possible.

Influence on ability to driving of motor transport and to control of mechanisms
Influence on ability to driving of motor transport and to control of mechanisms is noted.

Side effects:

- From the alimentary system: seldom - nausea, vomiting, loss of appetite, an abnormal liver function.
- From TsNS and a peripheral nervous system: seldom - a headache, dizziness, a polyneuritis.
- Allergic reactions: seldom - skin rash (including papular rashes).
Фурамаг® малотоксичен.

Interaction with other medicines:

It is not necessary to apply Furamag® along with Ristomycinum, chloramphenicol, streptocides (the risk of oppression of a hemopoiesis increases).
It is not recommended to appoint along with nitrofurans the drugs capable to acidify urine (including ascorbic acid, Calcii chloridum).

Contraindications:

— chronic renal failure of heavy degree;
— pregnancy;
— period of a lactation (breastfeeding);
— children's age up to 3 years (for this dosage form);
— hypersensitivity to drugs of nitrofuran group.

With care use drug at deficit glyukozo-6-fosfatdegidrogenazy.

Use of the drug FURAMAG® at pregnancy and feeding by a breast
Use of drug at pregnancy and in the period of a lactation (breastfeeding) is contraindicated.

Use at renal failures
The toxic phenomena as a result of use of drug are more often shown at patients with reduced secretory function of kidneys (intensity of metabolism of a furazidin increases).

Overdose:

Symptoms: manifestations of neurotoxic character, ataxy, tremor.

Treatment: it is necessary to drink a large amount of liquid. For stopping of acute symptoms use antihistaminic drugs. For prevention of neuritis purpose of vitamins is possible (Thiamini bromidum).

Storage conditions:

Drug should be stored in the unavailable to children, dry, protected from light place at a temperature not above 25 °C.

Issue conditions:

According to the recipe

Packaging:

Capsules on 25 or 50 mg of active ingredient on 30 capsules in packaging.